Cervical Dystonia market size was valued approximately USD 303 million in 2022

The Cervical Dystonia Market is expected to grow significantly from 2023-2034, driven by rising disease awareness and an expanding elderly population. Diagnosis continues to rely solely on clinical evaluation and patient history, as no laboratory or imaging test can definitively confirm the disorder.

The market is currently dominated by botulinum toxin injections, considered the gold-standard treatment, along with oral therapies such as benzodiazepines, anticholinergics, and muscle relaxants. Five major therapies - Dysport, Daxxify, Botox, Xeomin, and Myobloc/Nerbloc are FDA-approved for cervical dystonia. Although botulinum toxin injections provide strong symptom relief, their effects are temporary, require repeat dosing every few months, and some patients may develop treatment resistance over time.

In 2022, the United States led the Cervical Dystonia Market across the 7MM, with a valuation of USD 222.2 million, projected to rise by 2034. AbbVie’s BOTOX held the largest market share (USD 157.7 million) due to its first-mover advantage and long-standing dominance.

DelveInsight’s “Cervical Dystonia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Cervical Dystonia, historical and forecasted epidemiology as well as the Cervical Dystonia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Cervical Dystonia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cervical Dystonia Market Forecast

Some of the key facts of the Cervical Dystonia Market Report: 

• The Cervical Dystonia market size was valued approximately USD 303 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In 2022, Japan recorded approximately 3,478 diagnosed prevalent cases of cervical dystonia. DelveInsight's analysis indicates an expected decline in these cases by 2034.
• DelveInsight's projections suggest that there were about 106,252 diagnosed prevalent cases of cervical dystonia across the 7MM in 2022. It is anticipated that these numbers will rise over the study period spanning from 2020 to 2034.
• In the EU4 and the UK, Germany had the highest number of diagnosed prevalent cases of cervical dystonia, totaling approximately 21,172 cases in 2022. Following Germany, the UK had nearly 7,932 cases, while Spain had the lowest number of cases, around 2,688.
• In 2022, Japan had approximately 3,478 diagnosed prevalent cases of cervical dystonia. According to DelveInsight’s analysis, it is projected that these diagnosed prevalent cases will decrease by 2034.
• In 2022, there were roughly 3,478 diagnosed prevalent cases of cervical dystonia in Japan. DelveInsight’s analysis suggests that these cases are anticipated to decline by 2034.
• Key Cervical Dystonia Companies: AEON Biopharma, Daewoong Pharmaceuticals, Revance Therapeutics, Inc., Allergan, Ipsen, Merz Pharma, Medy-Tox, and others
• Key Cervical Dystonia Therapies: ABP-450, DaxibotulinumtoxinA, ABP-450, Medytoxin, Botulinum toxin A, Dysport® (abobotulinumtoxinA), Xeomin®, NT 201, MT10109, and others
• The Cervical Dystonia epidemiology based on gender analyzed that as per the National Organization for Rare Disorders (2023), cervical dystonia affects women approximately twice as often as men.
• The Cervical Dystonia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cervical Dystonia pipeline products will significantly revolutionize the Cervical Dystonia market dynamics.

Cervical Dystonia Overview

Cervical dystonia, also known as spasmodic torticollis, is a neurological movement disorder characterized by involuntary muscle contractions in the neck that cause abnormal movements and positions of the head and neck. These muscle contractions can lead to twisting, tilting, or turning of the head in various directions, resulting in pain, discomfort, and difficulty with daily activities.

Get a Free sample for the Cervical Dystonia Market Forecast, Size & Share Analysis Report

Cervical Dystonia Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Cervical Dystonia Epidemiology Segmentation:

The Cervical Dystonia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Prevalence of Cervical Dystonia
• Prevalent Cases of Cervical Dystonia by severity
• Gender-specific Prevalence of Cervical Dystonia
• Diagnosed Cases of Episodic and Chronic Cervical Dystonia

Download the report to understand which factors are driving Cervical Dystonia epidemiology trends @ Cervical Dystonia Epidemiology Forecast

Cervical Dystonia Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cervical Dystonia market or expected to get launched during the study period. The analysis covers Cervical Dystonia market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Cervical Dystonia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Cervical Dystonia Therapies and Key Companies

• ABP-450: AEON Biopharma/ Daewoong Pharmaceuticals
• DaxibotulinumtoxinA: Revance Therapeutics, Inc.
• ABP-450: AEON Biopharma, Inc.
• Medytoxin: Medy-Tox
• Botulinum toxin A: Allergan
• Dysport® (abobotulinumtoxinA): Ipsen
• Xeomin®: Merz Pharmaceuticals GmbH
• NT 201: Merz Pharmaceuticals GmbH
• MT10109: Medy-Tox

Discover more about therapies set to grab major Cervical Dystonia market share @ Cervical Dystonia Treatment Landscape 

Cervical Dystonia Market Strengths

• Given that cervical dystonia primarily affects individuals between the ages of 40 and 60, the rising aging population in the 7MM is anticipated to fuel the growth of the cervical dystonia market.
• Growing awareness among medical professionals and the public about cervical dystonia as a neurological disorder may result in an earlier diagnosis and treatment initiation.

Cervical Dystonia Market Opportunities

• Current treatments only provide partial relief for some patients, therefore there exists opportunities for pharma players to develop therapies with improved efficacy, duration of action, and safety profiles.
• Companies can invest in research and development efforts to identify new therapeutic targets and treatment modalities for cervical dystonia, including biologics and gene therapies.

Scope of the Cervical Dystonia Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Cervical Dystonia Companies: AEON Biopharma, Daewoong Pharmaceuticals, Revance Therapeutics, Inc., Allergan, Ipsen, Merz Pharma, Medy-Tox, and others
• Key Cervical Dystonia Therapies: ABP-450, DaxibotulinumtoxinA, ABP-450, Medytoxin, Botulinum toxin A, Dysport® (abobotulinumtoxinA), Xeomin®, NT 201, MT10109, and others
• Cervical Dystonia Therapeutic Assessment: Cervical Dystonia current marketed and Cervical Dystonia emerging therapies
• Cervical Dystonia Market Dynamics: Cervical Dystonia market drivers and Cervical Dystonia market barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Cervical Dystonia Unmet Needs, KOL’s views, Analyst’s views, Cervical Dystonia Market Access and Reimbursement 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.